Evaluation of enterohepatic circulation of the bile acids in patients with non-alcoholic fatty liver disease
https://doi.org/10.31146/1682-8658-ecg-216-8-73-78
Abstract
The aim. To study the clinical manifestations and features of changes in the spectrum of the bile acids in bile and blood in patients with non-alcoholic fatty liver disease. Materials and methods. 54 patients with non-alcoholic fatty liver disease at the stage of steatosis were examined. The median age was 50 years (45; 55). Complaints, objective symptoms and the results of laboratory and instrumental studies of the liver were used to verify non-alcoholic fatty liver disease. The content of the bile acids in bile and blood was determined using an AmazonX mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Results. The majority of the examined patients (77,8%) with non-alcoholic fatty liver disease had subjective and objective symptoms of damage to the hepatobiliary system and intestines. According to the results of mass-spectrometry, a decrease in the total amount of primary free bile acids (cholic, chenodeoxycholic) and an increase in the total content of conjugated bile acids (glycocholic, glycodeoxycholic, taurocholic, taurodeoxycholic, ursodeoxycholic) in portions “B” and “C” bile, as well as blood compared with the control group. The concentration of acids conjugated with glycine was higher than that of taurine conjugates, while the correct ratio of glycine conjugates to taurine was observed (3: 1 and higher). Conclusion. Changes in the spectrum of the bile acids in bile and blood, firstly, is an indicator reflecting the violation of enterohepatic circulation, and, secondly, demonstrates the increasingly obvious importance of the bile acids in the pathogenesis of non-alcoholic fatty liver disease.
About the Authors
Ya. M. Vakhrushev
Izhevsk State Medical Academy
Russian Federation
Russian Federation
A. P. Lukashevich
Izhevsk State Medical Academy
Russian Federation
Russian Federation
E. V. Suchkova
Izhevsk State Medical Academy
Russian Federation
Russian Federation
References
1. Bueverov A. O., Bogomolov P. O. Nonalcoholic fatty liver disease without obesity: the problem to be solved. Therapeutic Archive. 2017;12(2):226-232. doi: 10/17116/terarkh20178912226-2325.@@ Буеверов А. О., Богомолов П. О. Неалкогольная жировая болезнь печени без ожирения: проблема, ожидающая решения. Терапевтический архив. 2017;12(2):226-232. doi: 10/17116/terarkh20178912226-2325.
2. Younossi Z. M., Koening А. В., Abdelatif D. A. et al. Global epidemiology of nonalcoholic fatty liver disease. Meta-analytic assement of prevalence, incidence and outcomes. Hepatology, 2016;64(1):73-84. doi: 10.1002/hep.28431.
3. Zhirkov I. I., Gordienko A. V., Serdyukov D. Yu., et al. Key points of etiopathogenesis of non-alcoholic fatty liver disease. Bulletin of the Russian Military Medical Academy, 2019;2(66):219-222. (In Russ.)@@ Жирков И. И., Гордиенко А. В., Сердюков Д. Ю. и соавт. Ключевые моменты этиопатогенеза неалкогольной жировой болезни печени. Вестник Российской военно-медицинской академии. 2019;2(66):219-222.
4. Maevskaya M. V., Ivashkin V. T., Ivashkin K. V., et al. Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy. Therapeutic Archive. 2019;91(2):8-117. (In Russ.) doi: 10.26442/00403660.2019.02.000122.@@ Маевская М. В., Ивашкин В. Т., Ивашкин К. В. и соавт. Неалкогольная жировая болезнь печени как причина и следствие кардиометаболических осложнений. Особенности фармакотерапии. Место урсодезоксихолевой кислоты. Терапевтический архив. 2019;91(2):8-117. doi: 10.26442/00403660.2019.02.000122.
5. Grinevich V. B., Kravchuk Yu.A., Ped’ V.I. et al. Carcinogenesis in patients with non-alcoholic fatty liver disease without cirrhosis: the role of bile acids and intestinal microbiota. Experimental and clinical gastroenterology. 2019;168(8):4-10. (in Russ.) doi: 10.31146/1682-8658-ecg-168-8-4-10.@@ Гриневич В. Б., Кравчук Ю. А., Педь В. И. и соавт. Канцерогенез у пациентов с неалкогольной жировой болезнью печени без цирроза: роль желчных кислот и кишечной микробиоты. Экспериментальная и клиническая гастроэнтерология. 2019;168(8):4-10. doi: 10.31146/1682-8658-ecg-168-8-4-10.
6. Miura K., Ohnishi Н. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J. Gastroenterol. 2014, vol. 21,20, no. 23, pp. 7381-7391. doi: 10.3748/wjg.v20.i23.7381.
7. Rolfe L. D.Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Reviews of Infectious Diseases. 1984;6(1): 73-79. doi: 10.1093/clinids/6.supplement_1.s73.
8. Mouzaki M., Comelli E. M., Arendt B. M. et al.Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;(58):120-127. doi: 10.1002/hep.26319.
9. Zhu L., Baker S. S., Gill C. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2012;(57):601-609. doi: 10.1002/hep.26093.
10. Minullina Z. S., Kieashko S. V., Sayfutdinov R. G. et al. The content of bile acids in the serum of patients with nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2015;121(9):24-28. (In Russ.)@@ Минуллина З. Ш., Кияшко С. В., Сайфутдинов Р. Г. и соавт. Содержание желчных кислот в крови при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2015;121(9):24-28.
11. Fuchs C., Claudel T., Trauner M. Bile acid-mediated control of liver triglycerides. Semin.Liver.Dis. 2013;33(4):330-342. doi: 10.1055/s-0033-1358520.
12. Grinevich V. B., Sas E. I. Physiological effects of bile acids.Russkii meditsinskii zhurnal. Meditsinskoe obozrenie. 2017;1(2):87-91. (In Russ.)@@ Гриневич В. Б., Сас Е. И. Физиологические эффекты желчных кислот. РМЖ. Медицинское обозрение. 2017;1(2):87-91. (In Russ.)
13. Efimenko N. V., Ledovskaya T. I., Fyodorova T. E., et al. Non-alcoholic fatty liver disease: Modern aspects of etiopathogenesis and treatment. Avicenna Bulletin. 2017;19(3):393-398. (In Russ.) doi: 10.25005/2074-0581-2017-19-3-393-398.@@ Ефименко Н. В., Ледовская Т. И., Федорова Т. Е. и соавт. Неалкогольная жировая болезнь печени: современные аспекты этиопатогенеза и лечения. Вестник Авиценны. 2017;19(3):393-398. doi: 10.25005/2074-0581-2017-19-3-393-398.
14. Ilchenko A. A. Bile acids in normal and pathology. Experimental and clinical gastroenterology. 2010;4:3-13. (In Russ.)@@ Ильченко А. А. Желчные кислоты в норме и при патологии. Экспериментальная и клиническая гастроэнтерология. 2010;4:3-13.
15. Mayevskaya Ye.A., Cheremushkin S. V., Krivoborodova N. A. et al. Small-intestinal bacterial overgrowth syndrome: from recent scientific data to everyday practice. Klinicheskie perspektivy gastroenterologii, gepatologii. 2013;5:29-40. (In Russ.)@@ Маевская Е. А., Черемушкин С. В., Кривобородова Н. А. и соавт. Синдром избыточного бактериального роста в тонкой кишке: от последних научных данных к рутинной практике. Клинические перспективы гастроэнтерологии, гепатологии. 2013;5:29-40.
16. Vakhrushev Ya.M., Lukashevich A. P., Gorbunov A. Yu., et al.Intestinal Mechanisms of Enterohepatic Circulation Disturbance of Bile Acids in Cholelithiasis. Аnnals of the Russian academy of medical sciences. 2017;72(2):105-111. (In Russ.) doi: 15690/vramn807.@@ Вахрушев Я. М., Лукашевич А. П., Горбунов А. Ю. и соавт. Интестинальные механизмы в нарушении энтерогепатической циркуляции желчных кислот при желчнокаменной болезни. Вестник Российской академии медицинских наук. 2017;72(2):105-111. doi: 10.15690/vramn807.
17. Hylemon P. B., Zhou H. P., Pandak W. M. et al. Bile acids as regulatory molecules. J. Lipid Res. 2009;50(8):1509-1520. doi: 10.1194/jlr.R900007-JLR200.
18. Matsubara T., Li F., Gonzalez F. J. FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 2013;368(1-2):17-29. doi: 10.1061/j.mce.2012.05.004.
19. Li F., Jiang C. T., Krauze K. W. et al. Microbiome remodeling leads tu inhibition of intestinal farnesoid X receptor signaling and decreased obesity. Nat.Commun. 2013, no. 4, pp. 2384. doi: 10.1038/ncomms.3384.
Review
For citations:
Vakhrushev Ya.M., Lukashevich A.P., Suchkova E.V. Evaluation of enterohepatic circulation of the bile acids in patients with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2023;(8):73-78. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-216-8-73-78
Views:
422
Email this article 